Gene therapy trial for patients with Fanconi anaemia to open at GOSH

22 Mar 2016, 5:24 p.m.

Dr Claire Booth

A clinical trial is to open at Great Ormond Street Hospital (GOSH) that will test the use of gene therapy during transplantation for the treatment of young people with Fanconi anaemia. The trial will be led by Dr Claire Booth, Dr Phil Ancliff and Professor Adrian Thrasher – who is the Gene, stem and cellular therapies Theme Lead at the Great Ormond Street BRC.

Fanconi anaemia is a life-limiting, inherited haematological disorder which causes bone marrow failure in childhood as well as other serious complications. Children can be treated with a bone marrow transplant but the success of this procedure depends on finding a well matched donor for the patient.

The clinical trial due to open at GOSH in the coming months will assess whether gene therapy could offer hope to children lacking a suitable donor for transplant.

Researchers will make use of the BRC-funded GMP facility to genetically modify the patient’s own stem cells during the trial.

Fourth Annual NIHR GOSH BRC Image Competition - A Moment of Discovery

The Research and Innovation Communications team at GOSH and the NIHR GOSH Biomedical Research team invite you to enter our Research and Innovation Showcase: A Moment of Discovery.

New hope to prevent blindness in children with rare genetic disease

A new treatment that could prevent blindness in children with the CLN2 type Batten disease has been trialled by Clinicians at GOSH and University College London Great Ormond Street Institute of Child Health (UCL GOS ICH).

GOSH only hospital outside of North America to receive innovation funding award for AI

GOSH has been awarded the Amazon Web Services IMAGINE Grant: Children’s Health Innovation Award, to support artificial intelligence (AI) development and drive progress for children’s healthcare.

New clinical trial at GOSH gives hope to children with aggressive blood cancer

Researchers at GOSH and UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) are collaborating on a novel approach to clinical trials to give hope to children with an aggressive type of blood cancer, T-cell acute lymphoblastic leukaemia (T-ALL)